ClinicalTrials.Veeva

Menu
R

Retina Consultants San Diego | Poway, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

APL-2
Pegcetacoplan
EYP-1901
RGX-314
JNJ-81201887
Aflibercept
ABP 938
Bevasiranib
GT005
APL 3007

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 29 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidos...

Enrolling
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: APL-3007, pegcetacoplan (APL-2)
Other: Placebo, Syfovre

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling
Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)
Drug: Placebo
Drug: Pozelimab

This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previous...

Invitation-only
Diabetic Retinopathy, DR
Drug: Aflibercept
Drug: Standard of Care

This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previous...

Invitation-only
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Standard of Care
Drug: Ranibizumab

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in...

Enrolling
Geographic Atrophy Secondary to Age-related Macular Degeneration
Intermediate AMD
Device: i-Lumen AMD

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Active, not recruiting
Choroidal Neovascularization
Wet Age-related Macular Degeneration
Genetic: ABBV-RGX-314
Biological: Ranibizumab (LUCENTIS®)

The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.

Active, not recruiting
Non-neovascular Age-related Macular Degeneration
Age-Related Macular Degeneration
Biological: VOY-101

Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of th...

Enrolling
Diabetic Retinopathy
Drug: Topical Steroid
Drug: Artificial Tears

Trial sponsors

A
AbbVie logo
C
E
Janssen (J&J Innovative Medicine) logo
Amgen logo
Bayer logo
G
Ionis Pharmaceuticals logo
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems